Jak3 and the pathogenesis of severe combined immunodeficiency - PubMed (original) (raw)

Review

Jak3 and the pathogenesis of severe combined immunodeficiency

John J O'Shea et al. Mol Immunol. 2004 Jul.

Abstract

The discovery that Jak3 mutations are a significant cause of severe combined immunodeficiency (SCID), a rare inherited defect characterized by lymphopenia, has provided valuable insights into the functions of Jak3 in lymphoid development and function. The current therapy for patients suffering from Jak3 SCID is hematopoetic stem cell transplantation, although gene therapy trials have also been performed. In lieu of crystal structure data, these patient-derived mutations have aided in the elucidation of the functions of various structural components of Jak3. By virtue of its requirement for lymphoid functions, Jak3 makes a tantalizing target for immunosuppression and anti-cancer therapy. Herein, we discuss the normal actions of the gammac cytokines, the pathogenesis and treatment protocols for SCID, and finally, the production of a new, selective Jak3 inhibitor capable of preventing transplant rejection in two animal models. Further study of Jak3 will hopefully provide insights into the clinical treatment of patients suffering from immune-mediated diseases.

PubMed Disclaimer

Similar articles

• Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
  Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Pesu M, et al. Immunol Rev. 2005 Feb;203:127-42. doi: 10.1111/j.0105-2896.2005.00220.x. Immunol Rev. 2005. PMID: 15661026 Review.
• Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene.
  Villa A, Sironi M, Macchi P, Matteucci C, Notarangelo LD, Vezzoni P, Mantovani A. Villa A, et al. Blood. 1996 Aug 1;88(3):817-23. Blood. 1996. PMID: 8704236
• Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.
  Notarangelo LD, Mella P, Jones A, de Saint Basile G, Savoldi G, Cranston T, Vihinen M, Schumacher RF. Notarangelo LD, et al. Hum Mutat. 2001 Oct;18(4):255-63. doi: 10.1002/humu.1188. Hum Mutat. 2001. PMID: 11668610 Review.
• Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.
  Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ, Leonard WJ. Russell SM, et al. Science. 1995 Nov 3;270(5237):797-800. doi: 10.1126/science.270.5237.797. Science. 1995. PMID: 7481768
• Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain.
  Mella P, Schumacher RF, Cranston T, de Saint Basile G, Savoldi G, Notarangelo LD. Mella P, et al. Hum Mutat. 2001 Oct;18(4):355-6. doi: 10.1002/humu.1199. Hum Mutat. 2001. PMID: 11668621

Cited by

• Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.
  Cetkovic-Cvrlje M, Olson M, Ghate K. Cetkovic-Cvrlje M, et al. Cell Mol Immunol. 2012 Jul;9(4):350-60. doi: 10.1038/cmi.2012.20. Epub 2012 Jun 25. Cell Mol Immunol. 2012. PMID: 22728763 Free PMC article.
• The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.
  Wang H, Brown J, Gao S, Liang S, Jotwani R, Zhou H, Suttles J, Scott DA, Lamont RJ. Wang H, et al. J Immunol. 2013 Aug 1;191(3):1164-74. doi: 10.4049/jimmunol.1203084. Epub 2013 Jun 24. J Immunol. 2013. PMID: 23797672 Free PMC article.
• Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
  Raivola J, Hammarén HM, Virtanen AT, Bulleeraz V, Ward AC, Silvennoinen O. Raivola J, et al. Front Oncol. 2018 Dec 3;8:560. doi: 10.3389/fonc.2018.00560. eCollection 2018. Front Oncol. 2018. PMID: 30560087 Free PMC article.
• Cytokine signaling modules in inflammatory responses.
  O'Shea JJ, Murray PJ. O'Shea JJ, et al. Immunity. 2008 Apr;28(4):477-87. doi: 10.1016/j.immuni.2008.03.002. Immunity. 2008. PMID: 18400190 Free PMC article. Review.
• Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
  Meyer SC, Levine RL. Meyer SC, et al. Clin Cancer Res. 2014 Apr 15;20(8):2051-9. doi: 10.1158/1078-0432.CCR-13-0279. Epub 2014 Feb 28. Clin Cancer Res. 2014. PMID: 24583800 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • Genetic Alliance
  • MedlinePlus Health Information